GSE91061, which including 109 melanoma samples with anti-CTLA4 and anti-PD1 therapy demonstrated patients with complete response (CR) or partial response (PR) had a lower riskscore than those with stable disease (SD) or progressive disease (PD) (Fig. 10A). This evidence concerns the gene CTLA4 and melanoma.